Earnings summaries and quarterly performance for INTEGRATED BIOPHARMA.
Executive leadership at INTEGRATED BIOPHARMA.
Board of directors at INTEGRATED BIOPHARMA.
Research analysts covering INTEGRATED BIOPHARMA.
Recent press releases and 8-K filings for INBP.
Integrated BioPharma Reports Q1 2026 Financial Results
INBP
Earnings
Demand Weakening
- Integrated BioPharma, Inc. reported revenue of $12.7 million for the quarter ended September 30, 2025, marking a 6.6% decrease from $13.6 million in the prior year quarter.
- The company's net income for the quarter ended September 30, 2025, was approximately $0.1 million, resulting in $0.00 diluted net income per common share, compared to $0.3 million and $0.01 per share in the quarter ended September 30, 2024.
- Revenue from the two largest customers in the Contract Manufacturing Segment constituted approximately 87% of total revenue for the quarter ended September 30, 2025.
Nov 10, 2025, 8:54 PM
Integrated BioPharma Reports Q4 and Fiscal Year Ended June 30, 2025 Results
INBP
Earnings
Revenue Acceleration/Inflection
- Integrated BioPharma, Inc. (INBP) reported its financial results for the quarter and fiscal year ended June 30, 2025.
- For the quarter ended June 30, 2025, revenue increased by 11.8% to $14.2 million compared to the prior year, but the company experienced a net loss of $0.2 million or $(0.01) per diluted share.
- For the fiscal year ended June 30, 2025, revenue increased by 8.0% to $54.3 million, and net income was $808,000 or $0.03 per diluted share.
- Operating income for the fiscal year ended June 30, 2025, was approximately $0.6 million, an increase from $0.3 million in the prior fiscal year.
Sep 23, 2025, 7:42 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more